XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
The trial is a single arm, single-center, non-randomized clinical trial which is designed to evaluate the efficacy and safety of XLCART001 in treatment of relapsed/refractory/high-risk B-cell malignancy subjects
Lymphoma, B-Cell|Leukemia, B-cell
BIOLOGICAL: chimeric antigen receptor T cells
Overall response rate, Overall response rate (ORR) = complete response (CR) rate + partial response (PR) rate, ORR will be assessed at weeks 12., 12 weeks|Overall Survival, from the time of enrollment to death from any cause or the date of the last follow-up visit, 6 months,1 year, 2 years|Progression-free Survival, the time from enrollment to disease progression, death from any cause, or the date of the last follow-up visit, 12 weeks,6 months,1 year, 2 years|Event-free Survival, the time from enrollment to any events, or the date of the last follow-up visit, 12 weeks,6 months,1 year, 2 years
Dose-limiting toxicity (DLT), Non-haematological dose-limiting toxicities was any toxicity of grade 3 or higher occurring within 28 days of XLCART001 infusion judged possibly related to the treatment regimen.The following toxicities were not considered dose limiting toxicities: tumor lysis syndrome, abnormal electrolytes responding to supplementation, hypoalbuminemia, liver dysfunction resolving to â‰¤grade 2 within 14 days, transient (\<72 hours) grade 4 hepatic enzyme abnormality, and grade 3 or 4 fever or neutropenic fever., 28 days|Number of CAR-T cells, The number of CAR-T cells detected by flow cytometry and copy number of CAR-T cells tested by polymerase chain reaction, Day 1, Day 4, Day 7, Day 10, Day 14, Day 21, Day 28, 8 weeks, 12 weeks, 6 months, 1 years, 2 years|Duration of CAR-T cells, The duration of CAR-T cells detected by flow cytometry and copy number of CAR-T cells tested by polymerase chain reaction, Day 1, Day 4, Day 7, Day 10, Day 14, Day 21, Day 28, 8 weeks, 12 weeks, 6 months, 1 years, 2 years
The trial is a single arm, single-center, non-randomized clinical trial which is designed to evaluate the efficacy and safety of XLCART001 in treatment of relapsed/refractory/high-risk B-cell malignancy subjects